#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
proLékaře.cz

News

New drugs in CLL may also carry specific risks of adverse effects. How to minimize and manage them?

13. 3. 2020 Source: Chronic Lymphocytic Leukemia

The possibilities for the treatment of chronic lymphocytic leukemia (CLL) have greatly expanded in recent years. Significant changes have been brought particularly by small molecule-based therapeutic agents (inhibitors), which have shown significant efficacy in both previously untreated patients and those who have relapsed from CLL. When choosing the best treatment strategy for patients with CLL, it is of course necessary to consider the specific adverse effects of both new and previously used drugs, the overall condition of the patient,…

rodina_babicka_dcera

Safety and Efficacy of Different Antithrombotic Regimens in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention

Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI) require antithrombotic therapy for the prevention of atherothrombosis, stent…
13. 3. 2020 Source: Anticoagulant Treatment

Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’

The TRANSITION study has provided evidence on the safety and efficacy of administering sacubitril/valsartan to patients after acute decompensation of chronic heart failure with reduced ejection…
9. 3. 2020 Source: Chronic Heart Failure and Lipidology
medicína_nákres_střevo_střeva_zažívání_kreslené

Could candesartan counteract adverse intestinal changes induced by hypertension?

An experimental study published last year was the first to show that administration of candesartan may increase the tightness of epithelial junctions in the intestinal wall and positively affect the…
6. 3. 2020 Source: Sartans in the Treatment of Hypertension
holka_malá_dítě_logopedie_výslovnost_výuka_řeč_mluvení

Pharmacokinetics and Safety Profile of Bilastine in Patients Aged 6–11 Years –⁠ Findings from Post-hoc Analysis of Studies

The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in children over 6 years old. Post-hoc analyses of two clinical…
4. 3. 2020 Source: Allergic Reactions
medicina_zena_zily_tromboza_nohy_doktor_vysetreni

A Brief History of Deep Vein Thrombosis Treatment –⁠ From Antiquity to the Present

Deep vein thrombosis is among the common diseases that have accompanied humanity since its inception. Due to the low specificity of its clinical presentation (in contrast to, for example, varicose…
4. 3. 2020 Source: Prevention of Thrombosis in Surgery
operace_kolene

Current Recommendations of the American Society of Hematology for the Prevention of Thromboembolic Disease and Duration of Prophylaxis in Patients Undergoing Major Surgery

At the end of 2019, new recommendations were published by the American Society of Hematology (ASH) for the prevention of thromboembolic disease (VTE) in hospitalized patients. The new guidelines also…
4. 3. 2020 Source: Prevention of Thrombosis in Surgery
Úspora pro pojištěnce

More Patients Will Now Have Access to Incontinence Aids

Since December of last year, new rules have been in effect for the prescription of medical aids prescribed through vouchers, including aids for urine collection and voiding. The new rules are…
3. 3. 2020 Source: Incontinence
infekce

Assessment of Infection Risk in Patients with Multiple Sclerosis Treated with Various DMDs

Although the increased risk of infections with some disease-modifying drugs (DMDs) is known, we still lack sufficient real-world clinical data to evaluate and compare the risk levels of individual…
3. 3. 2020 Source: Multiple Sclerosis
cukrovka, diabetes

Effects of Telmisartan on Vascular Endothelial Functions, Inflammation Parameters, and Insulin Resistance in Patients with CHD and DM

Patients with coronary heart disease (CHD) and diabetes mellitus (DM) often have dysfunctional vascular endothelium, increased inflammatory markers, and insulin resistance. The study presented below…
2. 3. 2020 Source: Sartans in the Treatment of Hypertension
Ledviny a diagnóza

Metabolic Effect of Telmisartan and Candesartan in Kidney Transplant Patients

Increasing cardiovascular risk from complex causes warrants a comprehensive intervention. A prospective randomized crossover study compared the effects of telmisartan and candesartan on lipid and…
2. 3. 2020 Source: Sartans in the Treatment of Hypertension

Favorable effect of linagliptin on renal endothelial functions in patients with type 2 diabetes mellitus

Diabetic nephropathy is the cause of up to 50% of cases of end-stage chronic kidney disease. The main pathological mechanism involved in the development of the early stage of diabetic nephropathy is endothelial...
1. 3. 2020 Source: Diabetes

Monitoring Limits in Prescribing Incontinence Aids is Essential

The amendment to the Public Health Insurance Act, which came into effect in December 2019, brought many changes in the reimbursement of medical aids through prescriptions. The methodology for…
29. 2. 2020 Source: Incontinence
Starší pacientka na konzultaci u lékařky

Comprehensive View on Care for Patients with Urostomy

Thanks to improvements in surgical techniques and shorter hospital stays, patients with a stoma are returning to their home environment and to the care of outpatient doctors sooner. Quality care in…
28. 2. 2020 Source: Ostomy
Starší žena vybírá inkontinenční pomůcku

The Patient Will Feel Comfortable Only with a Properly Chosen Absorption Aid

While before the approval of the amendment to the Public Health Insurance Act, it was possible to issue a prescription only for one type of aid firmly tied to a particular level of incontinence, now…
27. 2. 2020 Source: Incontinence
1 … 108 109 110 111 112 … 115
Filter by speciality
Remove filters
Popular this week
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#